Rechercher | DIAL.pr - BOREAL

Accès à distance ? S'identifier sur le proxy UCLouvain

Affichage: 2 résultats.

- Article de périodique
Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial.
Coiffier, Bertrand Osmanov, Evgenii A Hong, Xiaonan Scheliga, Adriana Mayer, Jiri Offner, Fritz Rule, Simon Teixeira, Adriana Walewski, Jan de Vos, Sven Crump, Michael Shpilberg, Ofer Esseltine, Dixie-Lee Zhu, Eugene Enny, Christopher Theocharous, Panteli van de Velde, Helgi Elsayed, Yusri A Zinzani, Pier Luigi André, Marc[UCL] (2011) The Lancet Oncology — Vol. 12, no.8, p. 773-84 (2011)
- Article de périodique
Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.
Chanan-Khan, Asher Cramer, Paula Demirkan, Fatih Fraser, Graeme Silva, Rodrigo Santucci Grosicki, Sebastian Pristupa, Aleksander Janssens, Ann Mayer, Jiri Bartlett, Nancy L Dilhuydy, Marie-Sarah Pylypenko, Halyna Loscertales, Javier Avigdor, Abraham Rule, Simon Villa, Diego Samoilova, Olga Panagiotidis, Panagiots Goy, Andre Mato, Anthony HELIOS investigators Van Den Neste, Eric[UCL] (2016) The Lancet Oncology — Vol. 17, no. 2, p. 200-211 (2016)